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Abstract: Background: The association between clinical events and
everolimus exposure in patients receiving reduced-exposure calcineurin
inhibitor therapy is poorly explored.
Methods: In a pre-planned, descriptive analysis of data from a
randomized controlled trial, events were correlated with everolimus
trough concentrations in 556 newly transplanted kidney transplant
patients receiving everolimus with reduced-exposure cyclosporine (CsA)
and steroids. Influence of everolimus exposure on clinical events was
stratified according to predefined time-normalized concentrations.
Results: The incidence of treated biopsy-proven acute rejection and graft
loss at month 12 was highest in patients with everolimus <3 ng/mL
(36.4% and 28.6%, respectively, vs. 9.1–15.3% and 0.9–5.0% with higher
concentration ranges). A higher mortality rate was observed in patients
with an everolimus trough concentration  12 ng/mL (10.0% vs. 1.7–
5.6% with lower concentration ranges). The lowest rates of renal
dysfunction (defined as poor renal function [estimated GFR, serum
creatinine] or proteinuria), wound healing events, peripheral edema,
new-onset diabetes mellitus, hypercholesterolemia and
hypertriglyceridemia were generally observed with everolimus trough
concentration in the range 3–8 ng/mL and CsA <100 ng/mL. Proteinuria
occurred most frequently in patients with very low or very high
everolimus trough concentrations.
Conclusions: These results support an exposure–response relationship
between clinical events and everolimus trough concentrations in kidney
transplant patients receiving reduced-exposure CsA.
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The mammalian target of rapamycin (mTOR)
inhibitors exert their immunosuppressive effect by
blocking growth factor-driven T-cell proliferation
(1, 2), complementing the early inhibition of IL-2
gene transcription by calcineurin inhibitors (CNIs).
This synergism between mTOR inhibitors and
CNIs permits CNI dose/exposure reduction (2)
and a series of studies has confirmed that use of an
mTOR inhibitor with reduced-exposure CNI
regimen incurs no loss of efficacy following kidney
transplantation (3–8).
Analyses of pharmacokinetic data from earlier
studies in which kidney transplant patients
received a fixed dose of the mTOR inhibitor ever-
olimus with standard-exposure cyclosporine (CsA)
showed a clear association between the everolimus
trough concentration and incidence of biopsy-pro-
ven acute rejection (BPAR) (9, 10). An increased
risk of BPAR was observed for everolimus trough
concentration below 3 ng/mL (9, 10). In contrast,
everolimus trough concentration >3 ng/mL
prevented more than 80% of BPAR episodes (10).
Similar analyses of the association between clini-
cal events and everolimus exposure when used in
combination with reduced CNI dose/exposure are
rare (11). The A2309 study was a 24-month trial in
which 833 de novo kidney transplant patients were
randomized to everolimus trough concentrations
between 3 and 8 ng/mL or between 6 and 12 ng/
mL with reduced CsA exposure or to stan-
dard CsA with mycophenolic acid (MPA) (5). A
pre-planned, descriptive analysis supported by post
hoc exploratory analyses was undertaken to corre-
late efficacy, renal dysfunction, and safety events
with everolimus and CsA concentrations and the
results are reported here.
Materials and methods
Study design and conduct
The study methodology has been described in
detail previously (5) and additional information is
shown in SDC. Briefly, in a 24-month, multicenter,
parallel-group, international, open-label trial, adult
recipients of a primary, de novo kidney transplant
were randomized to one of three treatment arms:
(i) everolimus 0.75 mg b.i.d. targeting a trough
concentration of 3–8 ng/mL with reduced CsA (ii)
everolimus 1.5 mg b.i.d. targeting a trough concen-
tration of 6–12 ng/mL with reduced CsA or (iii)
MPA as enteric-coated mycophenolate sodium
(myfortic®, Novartis Pharma AG, Basel, Switzer-
land) 720 mg b.i.d. with standard CsA. Only
patients randomized to receive everolimus and
reduced CsA were included in the current analysis.
The study was conducted in accordance with the
Declaration of Helsinki following approval from
the institutional review board at each center and
written informed consent was obtained from all
the patients. The study started in October 2005
with the last patient visit in August 2009.
Immunosuppression regimens
Reduced CsA exposure targeted a CsA trough con-
centration of 100–200 ng/mL starting at day 5
visit; 75–150 ng/mL starting at the month 2 visit;
50–100 ng/mL starting at the month 4 visit; and 25
–50 ng/mL starting at the month 6 visit and main-
tained thereafter. All patients received basiliximab
induction and corticosteroids were administered
according to local practice and patients were low
to moderate immunological risk.
Primary endpoint
The primary endpoint was efficacy failure at month
12 defined as treated BPAR (tBPAR), graft loss,
death, or loss to follow-up.
Definitions
Poor renal function or proteinuria at months 12
and 24 was defined as: (i) a low estimated glomeru-
lar filtration rate (eGFR) defined as eGFR
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<30 mL/min/1.73 m2 (MDRD formula (12)) (ii) a
decreased eGFR defined as a decrease in renal
function by >30% as compared to month 1 as
assessed by either eGFR (MDRD and Nankivell
(13) equations) or creatinine clearance (CrCl)
(Cockcroft-Gault (14) formula) (iii) a high serum
creatinine defined as  200 lM (2.28 mg/dL) after
month 1 and (iv) proteinuria defined as urinary
protein:creatinine ratio  300 mg/g (30 mg/mmol)
after month 1.
New-onset diabetes mellitus (NODM) (i.e.,
occurring in patients who were non-diabetics at the
time of transplant) was defined as (i) diabetes
reported as an adverse event >14 d after the date
of transplantation or (ii) a random glucose
 11 mM (200 mg/dL) 14 d after transplant
(excluding elevated glucose levels that resolved
within 14 d) or (iii) diabetes recorded as the reason
for diabetic medication given 14 d after transplan-
tation and lasting for 14 d or more. Hypercholes-
terolemia was defined as total cholesterol
 6.2 mM (239 mg/dL), hypertriglyceridemia as
triglycerides  5.6 mM (496 mg/dL), and low
testosterone in male patients as testosterone
<10 nM if age <50 yr or <7 nM if age  50 yr.
Statistical methods
No formal testing of differences between patient
subpopulations was undertaken. Such testing was
not considered statistically valid because (i)
patients were randomized either to the everolimus
3–8 or 6–12 ng/mL treatment groups and not to
the drug exposure subpopulations used in this
analysis and (ii) different numbers of patients were
in the trough concentration ranges.
All efficacy events were included in the analysis
as there were too few on-treatment efficacy events
to be considered for analysis alone. Renal and
safety events were included only in patients
remaining on treatment. Efficacy events (tBPAR,
graft loss and death) and renal events were assessed
at 12 and 24 months. Safety events (adverse events,
selected hematological events, and lipid and
hormone changes) were selected for analysis if they
occurred with an incidence  5% in the everolimus
group or were more frequent in the everolimus
treatment group than in the MPA cohort (p value
 0.1, chi-square test). Few safety events occurred
from month 12 to month 24, preventing a mean-
ingful interpretation of data, so safety analyses are
restricted up to month 12.
Data are based on centrally measured time-nor-
malized mean trough concentrations for everoli-
mus and CsA. Time-normalized mean trough
concentrations were calculated as ΣAi/(Dk  D0)
where Ai is the trapezoid area (1/2)[(Ci-1 + Ci)*
(Di  Di-1)] under the concentrations Ci-1 and Ci,
Di is the blood sampling day for Ci, i = 1,…, k.
D0 = 7 or the first trough concentration examina-
tion date when a trough was obtained after day 7.
Concentrations below the lower limit of quantifica-
tion (0.4 ng/mL) were set to 0.2 ng/mL. Data were
pooled for both everolimus treatment groups.
Time-normalized mean everolimus trough concen-
trations and time-normalized mean CsA trough
concentrations were calculated up to the occur-
rence of an event or for patients without event, the
last on-treatment value and for change in eGFR
from month 1 to month 12 or to the last on-treat-
ment sampling date.
The influence of everolimus or CsA exposure on
efficacy, renal, and safety events was assessed by
dividing the time-normalized mean trough concen-
trations into predefined ranges (<3, 3–6, 6–8, 8–12,
and  12 ng/mL for everolimus and <50, 50–100,
100–200, and  200 ng/mL for CsA). To assess
the influence of everolimus trough concentrations
on efficacy and renal events, median–effect analy-
ses (15) were performed. Post hoc Cox propor-
tional hazard regression modeling was used to
estimate the probability of tBPAR and high
urinary protein:creatinine ratio ( 300 mg/g
[30 mg/mmol]) at specified combinations of time-
normalized everolimus and CsA trough concentra-
tions, i.e., the predicted incidence of tBPAR and
high urinary protein:creatinine ratio was estimated
for specific everolimus concentrations (3, 6, 8, 10,
and 12 ng/mL) and CsA concentrations (50, 100,
150 and 200 ng/mL). The linear regression model
was applied to evaluate the predicted change in
eGFR from month 1 to month 12, using the same
specified values of everolimus and CsA concentra-
tions as for tBPAR. The last observation carry for-
ward (LOCF) method was used for missing eGFR
values at month 1 or month 12. The interaction
between everolimus and CsA trough concentration
was investigated in these regression models.
Analyses of the relationship between everolimus
exposure and efficacy or renal events were per-
formed on the pharmacokinetic efficacy popula-
tion, comprising all intent-to-treat patients (i.e., all
randomized patients) who provided any everoli-
mus or CsA trough concentration measurement.
Analyses of everolimus exposure and safety events
were performed on all patients in the safety popu-
lation (i.e., patients who received at least one dose
of study drug and provided a post-baseline safety
assessment) who provided any everolimus or CsA
trough concentration measurement after randomi-
zation. As only those patients with exposure data
available at the time of the event or who were
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event-free at the specified time point were included,
the total number of patients available for analysis
varies among events. Time-normalized values of
CsA concentration were calculated up to an event
or up to the last on-treatment value for event-free
patients. As the occurrence of acute rejection is
expected to be concentrated in the early post-trans-
plant period before protocol-mandated CsA expo-
sure reductions occurred, CsA exposure values will
be heavily skewed upward in patients who experi-
enced tBPAR. To account for this, an additional
analysis was performed that uses data up to day 45




Five hundred fifty-six patients were randomized
to receive everolimus (277 at 1.5 mg/d, 279 at
3.0 mg/d). The mean age was 45.5 yr and 66.2%
of patients were male with no marked differences
in demographics or baseline characteristics
between treatment groups (Table 1). At months
12 and 24, respectively, 490 (88.1%) and 470
(84.5%) everolimus-treated patients remained in
the study; 354 (63.7%) and 328 (59.0%) remained
on the study medication.
Efficacy events
Among the patients receiving everolimus, tBPAR
had occurred in 86 patients (15.5%), graft loss in
26 patients (4.7%), and death in 17 patients (3.1%)
by month 12. At month 24, the corresponding
numbers were 97 (17.4%), 33 (5.9%), and 19
(3.4%). The incidence of tBPAR was markedly
higher in patients with an everolimus trough con-
centration <3 ng/mL (36.4% at month 12, 47.6%
at month 24) but no difference in the incidence of
tBPAR was observed above 3 ng/mL except at
everolimus trough concentrations  12 ng/mL
where the incidence of tBPAR was lower (9.1% at
month 12, 10.0% at month 24) (Fig. 1A, Table 2).
Kaplan–Meier analysis of the proportion of
patients free from tBPAR in the <3, 3–6, 6–8, 8–
12, and  12 ng/mL groups were 55.9%, 85.2%,
84.0%, 86.2%, and 89.7%, respectively, at month
12 and 39.9%, 83.2%, 81.8%, 85.3%, and 89.7%
at month 24. Fig. 2A shows a three-dimensional
representation of the estimated probability of
tBPAR at month 1 at specified combinations of
time-normalized everolimus and CsA trough con-
centration based on data up to day 45 (i.e., the last
day of the month 1 study window prior to CsA
dose reduction) from the Cox model. Patients with
everolimus concentrations below 3 ng/mL at
month 1 showed higher incidences of tBPAR,
which were reduced with increasing concentrations
of CsA. In contrast, in patients with everolimus
concentrations  8 ng/mL at month 1, the inci-
dence of tBPAR was not strongly influenced by
CsA concentrations. Although the predicted prob-
abilities in Fig. 2A indicate visually the exposure-
response relationship between the incidence of
tBPAR, everolimus concentration and CsA con-
centration, this could not be demonstrated statisti-
cally in the current analysis. The effect of
everolimus trough concentrations, CsA trough
concentrations, and their interaction on the inci-
dence of tBPAR was statistically non-significant
(p = 0.259, 0.295 and 0.176, respectively). How-
ever, the study was not powered for this analysis
and the number of included events was small
because of the limited time frame of 45 d, which
was selected because CsA concentrations were
expected to be constant during this period as per
the study design.
The incidence of graft loss at months 12 and 24
was similar within the everolimus range of
3–12 ng/mL (Table 2), but below 3 ng/mL, the
incidence of graft loss greatly increased (28.6% at
month 12, 42.1% at month 24) (Fig. 1B). Eight
graft losses in patients with everolimus trough con-
centrations <3 ng/mL by month 24 were due to











Age, yr 45.7 (12.7) 45.3 (13.4) 45.5 (13.0)
Male, % 177 (63.9) 191 (68.5) 368 (66.2)
White, % 193 (69.7) 180 (64.5) 373 (67.1)
Cause of end-stage renal disease, n (%)
Hypertension/
nephrosclerosis
50 (18.1) 56 (20.1) 106 (19.1)
Glomerular disease 44 (15.9) 55 (19.7) 99 (17.8)
Diabetes mellitus 39 (14.1) 29 (10.4) 68 (12.2)
Polycystic disease 36 (13.0) 29 (10.4) 65 (11.7)
Unknown 33 (11.9) 37 (13.3) 70 (12.6)
Other 75 (27.1) 73 (26.2) 148 (26.6)
HLA mismatches 3.5 (1.54) 3.3 (1.59) 3.4 (1.57)
PRA (peak evaluation)
 20%, n (%)
17 (6.1) 13 (4.7) 30 (5.4)
Donor age, yr 41.4 (13.9) 41.1 (13.0) 41.2 (13.4)
Deceased donor (heart
beating), (n %)
128 (46.2) 126 (45.2) 254 (45.7)
CMV serology status, n (%)
D+/R+ 140 (50.5) 139 (49.8) 279 (50.2)
D+/R 30 (10.8) 28 (10.0) 58 (10.4)
D/R+ 36 (13.0) 44 (15.8) 80 (14.4)
D/R 62 (22.4) 53 (19.0) 115 (20.7)
Continuous variables are shown as mean (SD).
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acute vascular rejection (two), chronic rejection
(three including one presumed), renal artery
thrombosis (two) and non-compliance (one). A sin-
gle graft loss occurred at an everolimus trough
concentration  12 ng/mL due to acute rejection.
A similar pattern was observed for Kaplan–Meier
estimates of the proportion of patients free from
graft loss at month 12 (65.8%, 95.5%, 96.6%,
99.2%, and 94.7% in the <3, 3–6, 6–8, 8–12 and
 12 ng/mL groups, respectively) and month 24
(49.3%, 94.5%, 95.9%, 97.5%, and 94.7%, respec-
tively). Mortality was similar across the everolimus
exposure ranges except a higher incidence of mor-
tality was observed in patients with a trough con-
centration  12 ng/mL but the number of events
in this range was small (Fig. 1C, Table 2). The two
deaths that occurred at an everolimus trough con-
centration  12 ng/mL were caused by acute myo-
cardial infarction and sepsis. The only death in the
lowest everolimus range (<3 ng/mL) was the result
of sepsis.
Exploratory exposure–event analyses of everoli-
mus trough concentrations vs. efficacy failure
events showed a significant inverse relationship
between everolimus exposure at months 12 and 24
and the incidence of graft loss (median–effect logis-
tic regression for combined everolimus groups:
month 12, p = 0.007; month 24, p = 0.004). This
trend was mainly driven by a higher incidence of
graft loss below an average everolimus trough con-
centration of 4 ng/mL. No clear relationship was
observed between the everolimus trough concen-
tration and tBPAR at month 12 (the analysis was
not performed for tBPAR at month 24) or for
death at months 12 and 24, although the number
of events was low.
Renal events
Regardless of whether renal function was assessed
by eGFR, CrCl, or serum creatinine, more patients
had poor renal function at months 12 and 24 when
the everolimus exposure was <3 ng/mL (Table S1).
In contrast, proteinuria defined as >300 mg protein
per gram of creatinine was more frequent in
patients either under-exposed (<3 ng/mL) or over-
exposed ( 12 ng/mL) to everolimus (SCD,
Table 1). The numbers of patients with nephrotic-
range proteinuria ( 3000 mg/g [339 mg/mmol])
at month 12 (n = 8) and month 24 (n = 7) were
too low to permit a meaningful analysis by everoli-
mus exposure. A significant correlation was
observed between everolimus trough concentra-
tions and the incidence of proteinuria (higher
trough level leading to a higher rate of events) at
months 12 and 24 (p = 0.004 and p = 0.010 from
logistic regression, respectively) but no correlation
was observed for other definitions of renal dys-
function.
In general, as CsA concentrations increased,
more patients had poor renal function measured
by either low eGFR, decreased eGFR, decreased
CrCl, or high serum creatinine level (SDC,
Table 1). Poor renal function was observed in a
higher proportion of patients when CsA concentra-
tions were above 100 ng/mL regardless of everoli-
mus concentrations up to 12 ng/mL. A few




Fig. 1. Incidence of (A) treated biopsy-proven acute rejection
(BPAR) (B) graft loss (C) death according to predefined range
of mean time-normalized everolimus trough concentration at
month 12 post-transplant (pharmacokinetic efficacy popula-
tion).
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(<3 ng/mL) and high CsA concentrations had
worse renal function. Of note, many categories had
very few patients in the denominator making inter-
pretation of the results difficult. In addition, more
patients with high everolimus and CsA concentra-
tions had proteinuria (everolimus concentrations
 12 ng/mL with CsA concentrations >100 ng/
mL) (SDC, Table 1). Fig. 2B represents a three-
dimensional representation of the negative change
in eGFR from month 1 to month 12 at specified
combinations of time-normalized everolimus and
CsA trough concentrations from the linear regres-
sion model. Increasing concentrations of CsA were
significantly associated with a substantially greater
decline in eGFR (p = 0.077). In contrast, higher
everolimus concentrations did not show a signifi-
cant association with the change in eGFR
(p = 0.351). At low CsA concentrations (50 ng/
mL), a negligible change in eGFR was observed
over the first year post-transplant regardless of the
everolimus concentration. No statistically signifi-




Fig. 2. (A) Estimated probability of
treated biopsy-proven acute rejection
(tBPAR) at month 1 from Cox
proportional hazards model based on
data to day 45 (pharmacokinetic
efficacy population) (B) the negative
change in estimated glomerular
filtration rate (eGFR) (MDRD) from
month 1 to month 12 at specified
combinations of time-normalized
everolimus and cyclosporine (CsA)
trough concentration from the linear
regression model (pharmacokinetic
efficacy population – 12-month on-
treatment analysis) (C) estimated
probability of high urinary protein:
creatinine ratio ( 300 mg/g after
month 1) from Cox proportional
hazards model at specified
combinations of time-normalized
everolimus and CsA trough
concentration (pharmacokinetic
efficacy population – 12-month on-
treatment analysis). All graphs showed
predicted values at specified
combinations of time-normalized
everolimus trough concentration (3, 6,
8, 10 and 12 ng/mL) and CsA trough
concentration (50, 100, 150 and 200 ng/
mL) in the pharmacokinetic efficacy
population. For example, in Fig. 2A, a
patient with time-normalized
everolimus trough concentration of
8 ng/mL and time-normalized
everolimus trough concentration of
100 ng/mL would have a 4.0%
predicted probability of tBPAR.
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interaction (p = 0.288) contributed to the change
in eGFR. The estimated probability of high
urinary protein:creatinine at specified combina-
tions of time-normalized everolimus and CsA
trough concentrations from the Cox model, as
depicted in Fig. 2C, showed no significant associa-
tion with everolimus exposure (p = 0.751), but a
clear effect could be attributed to increasing CsA
exposure (p < 0.001). No significant interaction
between everolimus and CsA on proteinuria was
observed (p = 0.335).
Safety events
Safety events that met the criteria for analysis
(i.e., incidence  5% of patients in the everolimus
groups or higher incidence with everolimus than
MPA) were wound healing events, peripheral
edema, stomatitis/oral ulcers, NODM, hypercho-
lesterolemia, hypertriglyceridemia, and low testos-
terone in male subjescts. The lowest rates of
wound healing events, peripheral edema, NODM,
hypercholesterolemia and hypertriglyceridemia
were generally observed with everolimus trough
concentration in the range 3–8 ng/mL and CsA
<100 ng/mL (Table 3). When data from all
patients were analyzed, regardless of CsA expo-
sure, the incidence of wound healing events and
peripheral edema was lowest when everolimus
concentrations were in the range 3–8 ng/mL
(Table 3). No clear correlation was observed
between everolimus exposure on stomatitis/oral
ulcers or NODM. Hypercholesterolemia and
hypertriglyceridemia were frequent events across
all everolimus ranges (Table 3). Low testosterone
levels did not show any association with everoli-
mus exposure. In general, the incidence of wound
healing events, peripheral edema, stomatitis/oral
ulcers, NODM, and lipid disorders increased as
CsA exposure increased over most everolimus
ranges. The highest rates of hypercholesterolemia
and hyperlipidemia were observed in patients
with high exposure to both CsA and everolimus.
No trend was observed for low testosterone
levels.
Discussion
These results support an exposure–response
relationship between efficacy and safety and everol-
imus trough concentration within the range
3–12 ng/mL in low-to-moderate immunological
risk kidney transplant patients. Increasing everoli-
mus exposure above 3 ng/mL was associated with
some additional benefit in reducing the risk of
tBPAR. An inverse relationship was observed
between everolimus exposure and graft loss at
months 12 and 24, with a higher graft loss rate at
everolimus trough concentrations below 4 ng/mL
but as the absolute number of events was low,
particularly at higher everolimus concentrations,
this finding should be interpreted cautiously.
The decrease in eGFR over the first year post-
transplant was driven by rising CsA concentration
but not by increasing everolimus concentration.
At low CsA exposure (50 ng/mL), eGFR results
were excellent regardless of exposure to everoli-
mus (Fig. 2B). A previous analysis in kidney
transplant patients has observed only a minor
effect of everolimus on serum creatinine in
patients receiving standard-exposure CsA (10).
The lowest rate of proteinuria was observed in
patients with everolimus trough concentration in
the range 3–8 ng/mL.
Wound healing events and peripheral edema
occurred less frequently in the everolimus exposure
range 3–8 ng/mL than at higher concentrations.
Although no consistent correlation between ever-
olimus exposure and NODM was apparent, the
high incidence of NODM in patients with mean
everolimus concentration  12 ng/mL in the pres-
ence of CsA concentration  200 ng/mL was
noteworthy although absolute numbers were small
(4/6 patients). Hypercholesterolemia and hypertri-
glyceridemia were most frequent in patients with
CsA trough concentration  100 ng/mL and ever-
olimus trough concentration >8 ng/mL. In
summary, an increased risk of certain adverse
events was observed with everolimus trough
concentrations above 8 ng/mL, and particularly
above 12 ng/mL. This is consistent with findings
from a recent study of 285 de novo kidney
transplant patients randomized to everolimus 3–8
or 8–12 ng/mL, in which a higher rate of discon-
tinuations due to adverse events occurred in the
8–12 ng/mL arm (16).
Several limitations of the current report need to
be considered. Although this study was a largely
pre-planned (only the Cox modeling of everolimus
and CsA exposure correlations with efficacy and
safety events was performed post hoc) analysis of a
randomized trial, it is of descriptive nature; statisti-
cal comparisons were not valid due to potential
bias imposed by the different number of patients in
each subpopulation. In addition, only a few
patients had either very high or very low everoli-
mus trough concentrations. For example, in the
highest everolimus exposure group ( 12 ng/mL),
the rate of tBPAR (9.1% at month 12) was lower
than in any other group, but only 22 patients were
in this cohort. Also, graft failure and death
occurred rarely, so the results become less reliable.
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The ability to assess the impact of CsA exposure
based on this model was limited due to the nature
of the study design, i.e., CsA exposure was highest
in the early post-transplant period, when most
acute rejection events occurred. Thus, as CsA
exposure values were calculated up to the occur-
rence of an event, values would tend to be heavily
skewed upward in patients with BPAR. Renal dys-
function and adverse events are less time-depen-
dent than rejection, so renal and safety events
showed the expected pattern of increasing inci-
dences with rising CsA exposure (Table 3). Lastly,
the study was not blinded due to the need to adjust
everolimus and CsA exposure, and the analyses
based on adverse event-reporting may reflect inves-
tigator bias.
In conclusion, we observed inferior efficacy in
patients with low everolimus trough concentra-
tions and an increased rate of wound healing,
peripheral edema, and hypercholesterolemia at
higher exposure levels. These findings are con-
sistent with a relationship between everolimus
Table 3. Incidence of adverse events according to time-normalized cyclosporine (CsA) and everolimus mean trough concentration achieved to





Mean CsA concentration (ng/mL)
<50 50 to <100 100 to <200  200 All
Wound healing events <3 1/4 (25.0) 3/11 (27.3) 10/11 (90.9) 3/4 (75.0) 17/30 (56.7)
3–6 1/4 (25.0) 8/98 (8.2) 27/80 (33.8) 22/29 (75.9) 58/211 (27.5)
6–8 0/2 (0.0) 6/57 (10.5) 23/59 (39.0) 10/22 (45.5) 39/140 (27.9)
8–12 0/3 (0.0) 2/46 (4.3) 20/44 (45.5) 24/29 (82.8) 46/122 (37.7)
 12 0/0 0/3 (0.0) 7/12 (58.3) 9/10 (90.0) 16/25 (64.0)
All 2/13 (15.4) 19/215 (8.8) 87/206 (42.2) 68/94 (72.3) 176/528 (33.3)
Peripheral edema <3 4/6 (66.7) 4/10 (40.0) 6/8 (75.0) 4/5 (80.0) 18/29 (62.1)
3–6 7/9 (77.8) 16/83 (19.3) 47/89 (52.8) 24/31 (77.4) 94/212 (44.3)
6–8 0/3 (0.0) 9/51 (17.6) 26/46 (56.5) 22/30 (73.3) 57/130 (43.8)
8–12 0/2 (0.0) 9/35 (25.7) 24/42 (57.1) 22/26 (84.6) 55/105 (52.4)
 12 0/0 1/4 (25.0) 6/11 (54.5) 10/11 (90.9) 17/26 (65.4)
All 11/20 (55.0) 39/183 (21.3) 109/196 (55.6) 82/103 (79.6) 241/502 (48.0)
Stomatitis/oral ulcers <3 0/3 (0.0) 0/9 (0.0) 0/2 (0.0) 0/3 (0.0) 0/17 (0)
3–6 0/3 (0.0) 1/119 (0.8) 8/85 (9.4) 5/18 (27.8) 14/225 (6.2)
6–8 0/6 (0.0) 5/76 (6.6) 10/62 (16.1) 1/18 (5.6) 16/162 (9.9)
8–12 0/3 (0.0) 1/65 (1.5) 7/40 (17.5) 2/13 (15.4) 10/121 (8.3)
 12 0/0 0/10 (0.0) 0/9 (0.0) 0/2 (0.0) 0/21 (0)
All 0/15 (0) 7/279 (2.5) 25/198 (12.6) 8/54 (14.8) 40/546 (7.3)
New-onset diabetes mellitus <3 0/3 (0.0) 0/8 (0.0) 0/2 (0.0) 0/3 (0.0) 0/16 (0)
3–6 1/3 (33.3) 2/125 (1.6) 10/85 (11.8) 3/14 (21.4) 16/227 (7.0)
6–8 0/5 (0.0) 6/77 (7.8) 9/59 (15.3) 2/17 (11.8) 17/158 (10.8)
8–12 0/3 (0.0) 0/57 (0.0) 10/42 (23.8) 5/14 (35.7) 15/116 (12.9)
 12 0/0 0/9 (0.0) 1/10 (10.0) 4/6 (66.7) 5/25 (20.0)
All 1/14 (7.1) 8/ 276 (2.9) 30/198 (15.2) 14/54 (25.9) 53/542 (9.8)
Hypercholesterolemia <3 1/4 (25.0) 15/18 (83.3) 10/11 (90.9) 7/10 (70.0) 33/43 (76.7)
3–6 0/1 (0.0) 9/42 (21.4) 86/121 (71.1) 46/55 (83.6) 141/219 (64.4)
6–8 0/3 (0.0) 7/27 (25.9) 47/67 (70.1) 32/38 (84.2) 86/135 (63.7)
8–12 0/1 (0.0) 3/15 (20.0) 50/59 (84.7) 34/38 (89.5) 87/113 (77.0)
 12 0/0 0/2 (0.0) 9/11 (81.8) 18/19 (94.7) 27/32 (84.4)
All 1/9 (11.1) 34/104 (32.7) 202/269 (75.1) 137/160 (85.6) 374/542 (69.0)
Hypertriglyceridemia <3 0/3 (0.0) 1/9 (11.1) 2/3 (66.7) 2/5 (40.0) 5/20 (25.0)
3–6 0/2 (0.0) 5/108 (4.6) 27/95 (28.4) 8/21 (38.1) 40/226 (17.7)
6–8 0/6 (0.0) 2/66 (3.0) 15/58 (25.9) 8/23 (34.8) 25/153 (16.3)
8–12 0/4 (0.0) 2/55 (3.6) 15/46 (32.6) 10/17 (58.8) 27/122 (22.1)
 12 0/0 0/10 (0.0) 4/11 (36.4) 4/6 (66.7) 8/27 (29.6)
All 0/15 (0) 10/248 (4.0) 63/213 (29.6) 32/72 (44.4) 105/548 (19.2)
Low testosterone (males) <3 0/0 0/2 (0.0) 0/0 0/0 0/2 (0)
3–6 0/2 (0.0) 13/68 (19.1) 13/39 (33.3) 2/3 (66.7) 28/112 (25.0)
6–8 0/4 (0.0) 13/44 (29.5) 7/26 (26.9) 2/7 (28.6) 22/81 (27.2)
8–12 0/3 (0.0) 6/47 (12.8) 9/25 (36.0) 0/4 (0.0) 15/79 (18.9)
 12 0/0 0/9 (0.0) 1/3 (33.3) 0/0 1/12 (8.3)
All 0/9 (0) 32/170 (18.8) 30/93 (32.3) 4/14 (28.6) 66/286 (23.1)
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